SHENZHEN, China, Oct. 13 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com - The Company intends to release its next 90 to 180 day forward guidance concurrent with its profile launch on www.stockprofile.com .
The guidance report will cover further outstanding topics namely OTCBB up listing status, audit, forward stock split, vote, Pink Sheets (skull and bones) rank, stock chill, MindUp cancer project and split off together with other corporate matters. The report is quite comprehensive and should provide the issuer's followers with a clear road map as to where the company intends to get to and what it intends to accomplish in the next 90 to 180 days. More importantly the company will be meeting early next week with the principal representatives of the Canadian Pharmaceutical company in Belgrade Serbia in regards to the Slavica Bio Chem's MindUp cancer project and its planned split off. The company feels that this is a significant event that its followers should be made aware of.
StockProfile.com provides the investing public with a free unique information portal for investors who like to conduct their own research and make their own investment decisions. The platform allows users to review and investigate dynamic publicly traded companies in a user-friendly environment.
If you are interested in viewing HTDS profile, please visit www.StockProfile.com.
To be included in HTDS' e-mail database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk; Investor Relations Department, (302) 357-9915 (IR); 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A); Corporate Matters, www.minamargroup.com (M&A), www.minamargroup.net (IR)
SOURCE Hard to Treat Diseases
Advertisement
The guidance report will cover further outstanding topics namely OTCBB up listing status, audit, forward stock split, vote, Pink Sheets (skull and bones) rank, stock chill, MindUp cancer project and split off together with other corporate matters. The report is quite comprehensive and should provide the issuer's followers with a clear road map as to where the company intends to get to and what it intends to accomplish in the next 90 to 180 days. More importantly the company will be meeting early next week with the principal representatives of the Canadian Pharmaceutical company in Belgrade Serbia in regards to the Slavica Bio Chem's MindUp cancer project and its planned split off. The company feels that this is a significant event that its followers should be made aware of.
Advertisement
StockProfile.com provides the investing public with a free unique information portal for investors who like to conduct their own research and make their own investment decisions. The platform allows users to review and investigate dynamic publicly traded companies in a user-friendly environment.
If you are interested in viewing HTDS profile, please visit www.StockProfile.com.
To be included in HTDS' e-mail database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk; Investor Relations Department, (302) 357-9915 (IR); 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A); Corporate Matters, www.minamargroup.com (M&A), www.minamargroup.net (IR)
SOURCE Hard to Treat Diseases
